Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | ERN1 | O75460 | 6/20 | 0.39 |
| ▸ | FDPS | P14324 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 3/20 | 0.36 |
| ▸ | PTPRF | P10586 | 1/20 | 0.35 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1509971 | 0.87 | LMNA (0.38) | ALDH1A1ERN1TSHRBACE1MAPT | |
| SCHEMBL27140861 | 0.87 | LMNA (0.38) | ALDH1A1ERN1TSHRBACE1MAPT | |
| SCHEMBL1509904 | 0.85 | PTPN1 (0.34) | ALDH1A1ERN1FDPSMEN1POLB | |
| SCHEMBL13088871 | 0.84 | ALDH1A1 (0.35) | ALDH1A1ERN1FDPSMEN1POLB | |
| SCHEMBL2240164 | 0.84 | ERN1 (0.47) | ALDH1A1ERN1FDPSMEN1POLB | |
| SCHEMBL1478225 | 0.84 | ERN1 (0.47) | ALDH1A1ERN1FDPSTSHRPTPRF | |
| SCHEMBL13025551 | 0.82 | PTPN1 (0.37) | ALDH1A1ERN1FDPSMEN1POLB | |
| SCHEMBL5644897 | 0.81 | CLCN2 (0.38) | ALDH1A1ERN1FDPSMEN1HPGD | |
| SCHEMBL3205905 | 0.79 | BACE1 (0.45) | ALDH1A1ERN1FDPSBACE1PTPRF | |
| SCHEMBL34462800 | 0.79 | BACE1 (0.45) | ALDH1A1ERN1FDPSBACE1PTPRF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326744-A1 | PIPERAZINE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | FUJIFILM CORPORATION (JP) | 2025-10-23 | — | — | US | disclosed |
| CN-119816484-A | Novel piperazine derivative or salt thereof and pharmaceutical composition | 富士胶片株式会社 | 2025-04-11 | — | — | CN | disclosed |
| WO-2024043334-A1 | NOVEL PIPERAZINE DERIVATIVE OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION | 富士フイルム株式会社 | 2024-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326744-A1 | PIPERAZINE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | ABCB11, ABCC1, SLC11A2 | ALDH1A1 774/4885ERN1 3094/4885FDPS 1398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.